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Abstract 
Background: There is evidence to suggest that people with established psychotic 
disorders show impairments in the mismatch negativity induced by a frequency-
deviant sound (fMMN), and that these impairments worsen with the deterioration of 
psychotic symptoms. This study aimed to test whether individuals at ultra-high risk 
(UHR) for psychosis show pre-morbid impairments in fMMN, and if so, whether 
fMMN continues to deteriorate with transition to psychosis. Method: fMMN was 
recorded in a cohort of UHR individuals (n=42) and compared to healthy controls 
(n=29). Of the 27 UHR participants who returned for a second EEG session, six 
participants had transitioned to psychosis by 12-month follow-up (UHR-T) and were 
compared to the 21 participants who did not transition (UHR-NT). Results: fMMN 
amplitude was significantly reduced, relative to healthy controls, in the UHR cohort. 
Furthermore, UHR-T individuals showed a significant decrease in fMMN amplitude 
over the period from baseline to post-transition; this reduction was not observed in 
UHR-NT. Conclusions. These results suggest that fMMN is abnormal in UHR 
individuals, as has repeatedly been found previously in people with established 
psychotic disorders. The finding that fMMN impairment worsens with transition to 
psychosis is consistent with the staging model of psychosis; however, caution must 
be taken in interpreting these findings, given the extremely small sample size of the 
UHR-T group.   
 
 
Key words: Event-related potential (ERP), transition, psychosis, ultra high risk 
(UHR), mismatch negativity (MMN)  
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1. Introduction 
Mismatch negativity (MMN) is an event-related potential (ERP) elicited pre-
attentively in response to an unexpected deviant stimulus presented in a stream of 
invariant standard stimuli (Näätänen et al., 1978). The impairment in MMN amplitude 
constitutes one of the most robust and replicable findings in schizophrenia (for recent 
reviews see Erickson et al., 2016; Michie et al., 2016; Randeniya et al., 2017), and 
has been described as a “break-through biomarker” (Naatanen et al., 2015; see also 
Naatanen et al., 2016). Different forms of the MMN have been argued to be related 
to different facets of schizophrenia. For example, the MMN brought about by a 
change in the duration of the deviant sound compared to the standard appears to be 
related to more longstanding “trait” features of schizophrenia (McGorry et al., 2013). 
Furthermore, several studies have shown that the duration-MMN (dMMN) is reduced 
in individuals at ultra-high risk (UHR) for developing psychosis when compared to 
controls (Atkinson et al., 2012; Bodatsch et al., 2011; Higuchi et al., 2014; Jahshan 
et al., 2012; Murphy et al., 2013; Nagai et al., 2013; Pantlin and Davalos, 2016; 
Perez et al., 2014; Shaikh et al., 2012; Shin et al., 2009; Solís-Vivanco et al., 2014), 
with only two studies showing conflicting results (Higuchi et al., 2013; Mondragon-
Maya et al., 2013). Most interestingly, comparing dMMN in UHR individuals who 
transition to psychosis (UHR-T), relative to those that do not transition (UHR-NT), 
have revealed that the decrease in dMMN amplitude is significant only in UHR-T 
(Atkinson et al., 2012; Bodatsch et al., 2011; Higuchi et al., 2014; Higuchi et al., 
2013; Perez et al., 2014; Shaikh et al., 2012). As such, it has been suggested that 
this impairment could be used as a predictor of future transition to psychosis.  
In comparison, the MMN brought about by a change in the frequency of the 
deviant sound compared to the standard is regarded as more of a state marker of 
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psychosis (McGorry et al., 2013). A meta-analysis of 32 studies on the MMN in 
schizophrenia and first-episode psychosis reports that effect sizes of frequency MMN 
(fMMN) were significantly correlated with duration of illness, indicating that the fMMN 
amplitude attenuation could reflect disease progression (Umbricht and Krljes, 2005). 
While some studies have found the fMMN to be intact in first-episode psychosis 
patients (Devrim-Ucok et al., 2008; Koshiyama et al., 2017; Magno et al., 2008; 
Mondragon-Maya et al., 2013; Salisbury et al., 2007; Salisbury et al., 2002; Todd et 
al., 2007; Umbricht et al., 2006; Valkonen-Korhonen et al., 2003), other studies have 
identified fMMN abnormalities in first-episode psychosis patients (Bodatsch et al., 
2011; Oades et al., 2006; Perez et al., 2014). This latter finding is consistent with 
numerous previous studies which have identified fMMN abnormalities in patients with 
chronic schizophrenia (See meta-analysis by Umbricht and Krljes, 2005). A few 
studies have also observed reduced fMMN in UHR when compared to healthy 
controls (Carrion et al., 2015; Perez et al., 2014). In light of the evidence for fMMN 
abnormalities in patients with long-term psychotic disorders, combined with the 
preliminary evidence for fMMN deficits in UHR individuals, the first aim of the current 
study was to investigate whether UHR individuals also exhibit fMMN deficits relative 
to healthy controls.  
In regards to the question of whether fMMN is a state marker of psychosis: 
Salisbury et al. (2007) suggested that fMMN impairment worsens with deterioration 
of illness in chronic schizophrenia patients. This hypothesis has only been directly 
tested once in UHR individuals (Atkinson et al., 2017). In this study, a relatively low 
proportion (10%) of UHR participants transitioned to psychosis, and no significant 
decline in fMMN amongst these individuals was observed. Thus, the second aim of 
the present study was to replicate the longitudinal design of Atkinson et al. (2017) 
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(2017), and measure the course of fMMN amplitudes in UHR individuals who 
transitioned to psychosis (UHR-T) over the follow-up period, compared to those UHR 
individuals who did not transition to psychosis over this period (UHR-NT). Consistent 
with previous studies (Bodatsch et al., 2011; Brockhaus-Dumke et al., 2005; 
Mondragon-Maya et al., 2013; Nagai et al., 2013), it was anticipated that fMMN 
would not be impaired at baseline in UHR-T participants compared to UHR-NT 
participants, but that a between-group difference would emerge as a decline in 
fMMN magnitude over time in the UHT-T group, consistent with the staging model of 
psychosis (McGorry et al., 2013).  
The present study formed part of a larger clinical trial investigating the effects 
of exposure to omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on brain function 
and transition to psychosis rates in UHR individuals. The concern that “false-positive” 
individuals (who would never have developed the illness) may be unduly exposed to 
antipsychotic medication and their potential side-effects has justified the use of more 
benign approaches such as ω-3 PUFAs (Nelson et al., 2014; van der Gaag et al., 
2013). Furthermore, ω-3 PUFA treatment in UHR has been shown to significantly 
reduce the transition-to-psychosis rates, and improve positive and negative 
symptoms relative to placebo (Amminger et al., 2010; Amminger et al., 2015), 
although these results have failed to replicate (McGorry et al., 2017). While the 
present study was not geared towards addressing this research question, and was 
underpowered to identify the efficacy ω-3 PUFAs on fMMN or transition rates, we 
nevertheless present the data here in case it could be of use in future meta-analytic 
studies investigating the efficacy of these compounds.  
To summarize, the two primary aims of the current study were to: (1) 
determine whether our UHR cohort displayed aberrant fMMN compared to healthy 
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controls; and (2) investigate whether there was any deterioration of the fMMN 
response following transition to psychosis. The third, supplementary aim of the study 
was to present our data on the association between ω-3 PUFA exposure and fMMN 
in the UHR group, in case it could be useful in future meta-analytic studies. 
 
2. Method 
2.1. Study Design  
Participants for this study were recruited from a larger pool of participants from the 
Neurapro study, a multicenter randomized-controlled trial of ω-3 PUFAs in UHR 
(Markulev et al., 2015; McGorry et al., 2017). Full clinical assessment, including an 
interview with the Comprehensive Assessment of At-Risk Mental States (CAARMS; 
Yung et al., 2005) to determine UHR status were conducted at baseline. Transition-
to-psychosis status was assessed every month during the 6-month treatment period 
and again at the 9- and 12-month follow-ups, using the exit criteria of the CAARMS 
of daily threshold psychotic symptoms for more than one week.  
Participants received either 2.8 g/day of marine fish oil, or placebo capsules, 
twice a day for 6 months. All participants also received 6-20 sessions of cognitive 
behavioral case-management (cognitive behavioural therapy within case-
management framework) administered by experienced clinicians. Full details about 
the Neurapro study, including clinical outcome measures and inclusion/exclusion 
criteria can be found elsewhere (Markulev et al., 2015; McGorry et al., 2017).  
EEG recordings were conducted at baseline, immediately following the 
treatment period (6 months), and/or as soon as possible after transition to psychosis. 
The EEG side study was approved by the Melbourne Health – Human Research 
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Ethics Committee. Written informed consent was obtained for every participant. 
Participation was voluntary and participants were reimbursed for their time. 
2.2. Participants 
Participants were recruited from the Personal Assessment and Crisis Evaluation 
(PACE) clinic at Orygen Youth Health (OYH) in Parkville, Victoria and from Western 
headspace in Sunshine, Victoria. They were eligible for inclusion in the study if they 
were aged 15-25 years, and satisfied one or more of the three operationally defined 
and validated UHR criteria: attenuated psychotic symptoms; Brief Limited 
Intermittent Psychotic Symptoms (BLIPS); and/or a trait risk factor. They also had to 
present with a 30% decrease or sustained chronically low functioning over the past 
year (Yung et al., 2004) as measured with the Social and Occupational Functioning 
Assessment Scale (SOFAS; Goldman et al., 1992). Of the 106 participants recruited 
in the Neurapro study at the Melbourne site, 56 agreed to participate in the EEG side 
study.  
A group of 29 healthy controls was recruited via online advertisements or from a 
pool of control participants at Orygen. Healthy controls were also aged 15-25 years 
old but had no past or current mental illness.   
2.3. EEG Acquisition 
EEG data were recorded using Neuroscan software and a Neuroscan SynAmps 2 
amplifier (Neuroscan, El Paso, Texas) with internal filters set to 0.5-1000Hz. Data 
were continuously sampled at a rate of 1000 Hz from a 64-electrode Quick Cap in 
accordance with the 10-10 system. Eye movements were measured by placing non-
standard electrodes on the outer canthus of each eye for horizontal movement, and 
above and below the left eye for vertical movement. Each electrode was referenced 
to an electrode placed on the nose. 
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fMMN was elicited using an auditory oddball paradigm using the following 
parameters: standard sounds (90% of trials; 1000 Hz; 50 ms); frequency-deviant 
sounds (10% of trials; 1200 Hz; 50 ms). 3000 stimuli were presented in a pseudo-
randomised order (never two frequency-deviants in a row) with a stimulus onset 
asynchrony of 500 ms. All stimuli were presented binaurally through professional 
headphones (Sennheiser HD 280 Pro) whilst participants sat in a sound-proof room 
watching a silent video.  
2.4. EEG Data Processing  
Data were processed using BrainVision Analyzer version 2.1. Data measured at 
each electrode were re-referenced to the linked mastoids and filtered using a 0.1 
to 20 Hz phase-shift free Butterworth filter (48 dB/Oct slope), as well as a 50 Hz 
notch filter. Epochs from -100 to 600 ms relative to stimulus onset were extracted 
and baseline-corrected to their mean voltage from -100 to 0 ms. Epochs were 
corrected for eye blink and movement artefacts (Gratton et al., 1983). All epochs with 
signals exceeding peak-to-peak amplitudes of 200 microvolts at any channel were 
excluded, as well as any standards that immediately followed a frequency-deviant. 
ERPs for each stimulus (standard, frequency-deviant) were computed for each 
participant. The fMMN was defined on the grand-averaged ERPs as the negative 
peak in the difference waves between frequency-deviants and standards (i.e., 
frequency deviant-minus-standard) between 130 and 200 ms at the frontal electrode 
Fz (Duncan et al., 2009; Näätänen et al., 2007).  
2.5. Statistical Analyses 
Differences in baseline characteristics of participants were assessed by Student’s t-
test or chi-squared test as appropriate using IBM® SPSS® Statistics Version 22. 
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EEG data analyses were conducted using Dell Statistica version 13. The first 
analysis only used the baseline data and compared the fMMN response of all UHR 
individuals (regardless of subsequent transition) against that of controls within a 2 x 
2 ANOVA, with a single repeated-measures factor (stimulus type: standard or 
frequency-deviant) and a single between-subjects factor (group: UHR or controls).  
The second analysis made use of both measurement occasions in order to 
assess whether fMMN magnitude differed between UHR-T and UHR-NT 
participants, and between measurement occasions (prior to transition, post-
transition). The data were analyzed using a 2 x 2 mixed factors ANOVA, with a 
single centered, nuisance covariate. The between-subjects factor was group 
(transitioned, no transition), the repeated-measures factor was time of measurement 
(baseline, post-transition), and the nuisance covariate was delay (the number of 
days between baseline and post-transition measurements). The covariate was 
added because the time of the “post-transition” measurement differed between 
individuals, although the same inferential conclusions held if the raw data were 
analyzed without this covariate. Type I error was controlled at α = 0.05 throughout.  
As discussed above, our study also explored the question of whether fMMN 
response of those UHR individuals exposed to ω-3 PUFA treatment differed from 
those who were allocated to the placebo group. This research question formed part 
of a larger study investigating the efficacy of ω-3 PUFAs in improving clinical 
outcome in UHR individuals (McGorry et al., 2017). Unfortunately the present study 
was underpowered to detect between-group differences, and thus we did not 
perform statistical analyses on this data and do not interpret the results below. 
However, we have provided the descriptive statistics and effect sizes in the Results 
section.  
 10 
3. Results 
3.1. The UHR group displays aberrant fMMN when compared to controls 
Comparisons between controls and UHR participants were conducted using the 
baseline recordings, i.e., prior to the start of treatment in the UHR group, to avoid 
any confounding effect of treatment. Out of the 56 Neurapro participants who agreed 
to participate in the EEG side study, 10 did not attend their baseline recording 
session and the baseline data from four participants had to be excluded from 
analyses due to poor data quality. Analyses were conducted on the remaining 42 
UHR participants and 29 healthy controls. The female:male ratio was not different 
between the two groups (controls, 15:14; UHR, 26:16). Mean age was slightly lower 
in the UHR group (17.6 ± 2.3 years) than in the control group (18.7 ± 2.1 years; p = 
.038). As expected, functioning score determined with the SOFAS were much lower 
in the UHR group (56.9 ± 10.4) compared to the controls (88.9 ± 5.1; p < .001).  
The average evoked potentials measured at Fz for both controls and UHR 
following the presentation of the standard and frequency-deviant sounds, as well as 
the standard-minus-frequency-deviant difference wave, are illustrated in Figure 1A. 
Figure 1B shows the mean ERP amplitudes between 130 ms and 200 ms in the two 
groups. The inferential analyses of the mean amplitude data revealed a main effect 
of stimulus-type, F(1,69) = 218.36, p < .001, 95% CI[7.53, 9.88], ηP
2 = .76, indicating 
an overall MMN effect averaged across groups. There was no main effect of group, 
F < 1. 
The interaction contrast showed that the difference between the standard- and the 
frequency-deviant-evoked wave (i.e., fMMN magnitude) of the UHR group was 
smaller than that of controls at baseline, F(1,69) = 4.86, p = .03, 95% CI[.12, 2.47], 
ηP
2 = .07. There were no significant differences between the groups when the 
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frequency-deviant sounds were considered in isolation, F< 1, but there was a non-
significant trend towards the standard sounds giving a larger voltage in the control 
group than in the UHR group, F(1,69) = 3.85, p = .05, 95% CI[-.01, 1.48], ηP
2 = .05.  
3.2. fMMN response deteriorates with the transition to psychosis   
Of the 27 UHR individuals who attended two EEG sessions, six participants 
transitioned to psychosis by 12-month follow-up (the UHR-T group) and 21 
participants did not (the UHR-NT group). The transition-to-psychosis rate in this 
group was therefore 22.2%. Of the 15 UHR participants who did not attend the 
follow-up session, only two transitioned to psychosis at 12-month follow-up (13.3%). 
See Table 1 for participants’ characteristics at baseline. At follow-up, SOFAS scores 
were significantly higher in UHR-NT (66.7) compared to UHR-T (55.0; p = 0.03).  
The magnitude of the fMMN response for both groups (Figures 2A and 2B) was 
analyzed using an ANOVA. The main effect of group (UHR-T, UHR-NT) was not 
significant, F < 1. However, group significantly interacted with measurement 
occasion, F(1,24) = 4.77, p = .04, 95% CI[0.10, 3.43], ηP
2 = .17. Simple effect 
analyses were conducted to further investigate this interaction. In the six UHR-T 
individuals there was a significant decline in MMN magnitude over the study period 
of 1.14 microvolts (unweighted units), F(1,4) = 8.12, p = .046, 95% CI[0.03, 2.25], ηP
2 
= .67, whereas UHR-NT individuals showed a non-significant, numeric increase in 
MMN magnitude of 0.60 microvolts between measurements, F(1,19) = 2.09, p = .16, 
95% CI[-0.27, 1.47], ηP
2 = .10.  
Of the six UHR-T participants, three were allocated to the ω-3 PUFAs, whereas 
three were in the placebo group. Of the 21 UHR-NT participants, 13 took ω-3 PUFAs 
over the first 6-months of the study, whereas eight took placebo. Given the potential 
confound between treatment and transition status, a secondary analysis was 
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conducted with treatment condition (PUFAs vs. placebo) as a co-variate. This 
analysis confirmed that the significant interaction held; F(1,23) = 5.61, p = .03, 95% 
CI[0.24, 3.52], ηP
2 = .20. 
As there appeared to be a difference between UHR-NT and UHR-T at baseline, 
a simple effect contrast examined any differences between groups; no significant 
differences were found, F(1,25) = 1.61, p = .21, 95% CI[-0.75, 3.17], ηP
2 = .06. 
To summarise, those individuals who transitioned to psychosis showed a 
significant decline in MMN magnitude from baseline (i.e., before they exhibited 
psychotic symptoms) to immediately after exhibiting psychotic symptoms, whereas 
the UHR-NT group did not show a change in MMN magnitude over the six-month 
study period. 
3.3. Supplementary data: the relationship between exposure to ω-3 PUFAs and 
fMMN  
Of the 27 UHR individuals who provided two EEG measurements (i.e., baseline and 
post-transition or 6-month follow-up), 16 were assigned to the ω-3 PUFA group and 
11 were assigned to the placebo group. Four people transitioned before the 
treatment period was completed (i.e., within six months of baseline) and were thus 
omitted from these analyses as they did not provide a post-treatment measure. 
Three of these people were in the ω-3 PUFA group and one was in the placebo 
group.  
As the present study was underpowered to detect between-group differences, 
we have not performed inferential statistical analyses on this data. However, in case 
they may be of interest to the readers, the summary statistics for the fMMN data 
(mean, standard error, and 95% confidence intervals), as well as the demographics 
and clinical characteristics of the participants in the two treatment groups are 
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presented in Table 2.  The effect size of the between-group difference in fMMN 
difference score (i.e., fMMN post- minus pre-treatment) was d = 0.57. The raw data 
are available from the authors upon request for use in any future meta-analytic 
studies exploring the clinical utility of ω-3 PUFAs in UHR individuals. 
4. Discussion 
The current study presents two interesting observations. First, fMMN amplitude was 
significantly impaired in our UHR cohort relative to healthy controls. Second, 
individuals who transitioned to psychosis showed a significant fMMN deterioration, 
whereas UHR individuals who did not transition exhibited a relatively stable fMMN. 
However, the small sample sizes in the second analysis, particularly in the UHR-T 
group, means that this finding should be interpreted with caution until it can be 
replicated. 
Of the previous studies investigating fMMN in UHR (Atkinson et al., 2017; 
Bodatsch et al., 2011; Koshiyama et al., 2017; Mondragon-Maya et al., 2013; Nagai 
et al., 2013), to the best of our knowledge only one has shown decreased fMMN in 
UHR (Perez et al., 2014), consistent with the results of the present study. These 
studies in UHR have used either the CAARMS or the Structured Interview for 
Prodromal Symptoms (SIPS; Miller et al., 2002) to determine the eligibility of 
participants. The present study recruited at-risk samples who exhibited either 
reduced functioning, or chronically low functioning, as measured with the SOFAS. 
Given that reduced functioning is reliably correlated with reduced MMN amplitude in 
psychosis (Hermens et al., 2010; Jahshan et al., 2012; Kaur et al., 2013; Kawakubo 
and Kasai, 2006; Light and Braff, 2005a, b; Rasser et al., 2011), the additional 
specification of low functioning as an UHR criterion may be responsible for the lower 
mean fMMN amplitude observed.  
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Our results show that UHR-T individuals presented with a significant decline 
in fMMN magnitude from baseline to immediately after exhibiting psychotic 
symptoms, whereas the UHR-NT group did not show a change in fMMN magnitude 
over the follow-up period. The longitudinal aspect to our study is crucial because if 
we had only compared the UHR-T group to the UHR-NT cross-sectionally, no 
significant difference would have been observed and we would have missed the 
critical decline in the fMMN amplitude.  
The present data are consistent with the hypothesis that fMMN may be a state 
marker for psychosis. Indeed, the fMMN appears to illustrate the theoretical concept 
of the staging model (McGorry et al., 2013), in that impairment in fMMN worsens with 
increased symptomatology. The Umbricht and Krljes (2005) meta-analysis showed 
that the effect sizes of fMMN were significantly correlated with the duration of illness, 
indicating that fMMN amplitude attenuation could reflect disease progression. It was 
also shown that fMMN can be improved by the administration of N-acetyl-cysteine in 
schizophrenia patients (Lavoie et al., 2007), reinforcing its status as a state marker 
of the illness rather than a trait marker. The present observation of a decline in fMMN 
around the time of transition to psychosis also supports this hypothesis. To the best 
of our knowledge, only one other study has looked at the longitudinal changes in the 
fMMN following transition to psychosis, and their results showed no change in fMMN 
amplitude over time (Atkinson et al., 2017). Similar to the present report, their UHR-T 
group constituted of six individuals and, therefore, the statistical power for both 
studies is low. Replicating these results with a longitudinal design in a larger UHR 
cohort would be a worthwhile endeavor. 
There are a number of limitations that apply to the present study. The sample 
size for the UHR-T group was very small (n = 6), which limits the statistical power of 
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analyses and restricts the generalizability of the results. Recruitment in the UHR 
population remains challenging and future studies may benefit from data-pooling. A 
second and related issue concerns the time-bound criterion for conversion to 
psychosis employed in this study, which defined ‘conversion’ as the development of 
psychosis within 12 months of UHR assessment. Given that transition risk generally 
remains elevated two to three years from baseline assessment of UHR status 
(Fusar-Poli et al., 2012; Nelson et al., 2013), it is possible that this relatively strict 
criterion captured only a subset of the true sample of UHR converters in the present 
study. 
5. Conclusion 
The current study has shown that fMMN amplitude was significantly impaired relative 
to healthy controls in a UHR cohort presenting with relatively low functioning. 
Furthermore, UHR individuals who subsequently transitioned to psychosis showed a 
significant deterioration in fMMN following the worsening of their positive 
symptomatology, while UHR individuals who did not transition exhibited stable 
fMMN. While these results are consistent with the hypothesis that fMMN is a state 
marker of psychotic symptoms, it should be treated with caution until it can be 
replicated in a larger sample.  
6. Acknowledgements 
This work was supported by a grant from the University of Melbourne (SL) and a 
NARSAD grant (17537; TW). The Neurapro study was supported by the Stanley 
Medical Research Institute (07TGF-1102), the NHMRC Australia Program (566529) 
and the Colonial Foundation. BN was supported by a NARSAD Independent 
Investigator Grant from the Brain & Behavior Research Foundation, OG was 
 16 
supported by an Australian Research Council (ARC) grant (DE150100667), and TW 
is supported by a Career Development Fellowship from the NHMRC (APP1090507) 
and Discovery Projects from the ARC (DP140104394; DP170103094). We thank all 
of the participants and their families.  
7. Conflict of Interest 
The authors have no conflict of interest to declare. 
 17 
8. References 
Amminger, G.P., Schäfer, M.R., Papageorgiou, K., Klier, C.M., Cotton, S.M., Harrigan, S.M., 
Mackinnon, A., McGorry, P.D., Berger, G.E., 2010. Long-chain omega-3 fatty acids for indicated 
prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67(2), 
146-154. 
Amminger, G.P., Schafer, M.R., Schlogelhofer, M., Klier, C.M., McGorry, P.D., 2015. Longer-term 
outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun 6, 
7934. 
Atkinson, R.J., Fulham, W.R., Michie, P.T., Ward, P.B., Todd, J., Stain, H., Langdon, R., Thienel, R., 
Paulik, G., Cooper, G., Min, T.C., Schall, U., 2017. Electrophysiological, cognitive and clinical profiles 
of at-risk mental state: The longitudinal Minds in Transition (MinT) study. PLoS One 12(2), e0171657. 
Atkinson, R.J., Michie, P.T., Schall, U., 2012. Duration mismatch negativity and P3a in first-episode 
psychosis and individuals at ultra-high risk of psychosis. Biological psychiatry 71(2), 98-104. 
Bodatsch, M., Ruhrmann, S., Wagner, M., Muller, R., Schultze-Lutter, F., Frommann, I., Brinkmeyer, 
J., Gaebel, W., Maier, W., Klosterkotter, J., Brockhaus-Dumke, A., 2011. Prediction of psychosis by 
mismatch negativity. Biol Psychiatry 69(10), 959-966. 
Brockhaus-Dumke, A., Tendolkar, I., Pukrop, R., Schultze-Lutter, F., Klosterkotter, J., Ruhrmann, S., 
2005. Impaired mismatch negativity generation in prodromal subjects and patients with 
schizophrenia. Schizophrenia Research 73(2-3), 297-310. 
Carrion, R.E., Cornblatt, B.A., McLaughlin, D., Chang, J., Auther, A.M., Olsen, R.H., Javitt, D.C., 2015. 
Contributions of early cortical processing and reading ability to functional status in individuals at 
clinical high risk for psychosis. Schizophr Res 164(1-3), 1-7. 
Devrim-Ucok, M., Keskin-Ergen, H.Y., Ucok, A., 2008. Mismatch negativity at acute and post-acute 
phases of first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(3), 179-185. 
Duncan, C.C., Barry, R.J., Connolly, J.F., Fischer, C., Michie, P.T., Naatanen, R., Polich, J., Reinvang, I., 
Van Petten, C., 2009. Event-related potentials in clinical research: guidelines for eliciting, recording, 
and quantifying mismatch negativity, P300, and N400. Clin Neurophysiol 120(11), 1883-1908. 
Erickson, M.A., Ruffle, A., Gold, J.M., 2016. A Meta-Analysis of Mismatch Negativity in Schizophrenia: 
From Clinical Risk to Disease Specificity and Progression. Biol Psychiatry 79(12), 980-987. 
Fusar-Poli, P., Bonoldi, I., Yung, A.R., Borgwardt, S., Kempton, M.J., Valmaggia, L., Barale, F., 
Caverzasi, E., McGuire, P., 2012. Predicting psychosis: meta-analysis of transition outcomes in 
individuals at high clinical risk. Arch Gen Psychiatry 69(3), 220-229. 
Goldman, H.H., Skodol, A.E., Lave, T.R., 1992. Revising axis V for DSM-IV: a review of measures of 
social functioning. Am J Psychiatry 149(9), 1148-1156. 
Gratton, G., Coles, M.G., Donchin, E., 1983. A new method for off-line removal of ocular artifact. 
Electroencephalogr Clin Neurophysiol 55(4), 468-484. 
 18 
Hermens, D.F., Ward, P.B., Hodge, M.A., Kaur, M., Naismith, S.L., Hickie, I.B., 2010. Impaired 
MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog 
Neuropsychopharmacol Biol Psychiatry 34(6), 822-829. 
Higuchi, Y., Seo, T., Miyanishi, T., Kawasaki, Y., Suzuki, M., Sumiyoshi, T., 2014. Mismatch negativity 
and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state. Frontiers in 
behavioral neuroscience 8, 172. 
Higuchi, Y., Sumiyoshi, T., Seo, T., Miyanishi, T., Kawasaki, Y., Suzuki, M., 2013. Mismatch negativity 
and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PLoS 
One 8(1), e54080. 
Jahshan, C., Cadenhead, K.S., Rissling, A.J., Kirihara, K., Braff, D.L., Light, G.A., 2012. Automatic 
sensory information processing abnormalities across the illness course of schizophrenia. 
Psychological medicine 42(1), 85-97. 
Kaur, M., Lagopoulos, J., Lee, R.S., Ward, P.B., Naismith, S.L., Hickie, I.B., Hermens, D.F., 2013. 
Longitudinal associations between mismatch negativity and disability in early schizophrenia- and 
affective-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 46, 161-169. 
Kawakubo, Y., Kasai, K., 2006. Support for an association between mismatch negativity and social 
functioning in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30(7), 
1367-1368. 
Koshiyama, D., Kirihara, K., Tada, M., Nagai, T., Koike, S., Suga, M., Araki, T., Kasai, K., 2017. Duration 
and frequency mismatch negativity shows no progressive reduction in early stages of psychosis. 
Schizophr Res. 
Lavoie, S., Murray, M.M., Deppen, P., Knyazeva, M.G., Berk, M., Boulat, O., Bovet, P., Bush, A.I., 
Conus, P., Copolov, D., Fornari, E., Meuli, R., Solida, A., Vianin, P., Cuenod, M., Buclin, T., Do, K.Q., 
2007. Glutathione precursor, N-Acetyl-Cysteine, improves mismatch negativity in schizophrenia 
patients. Neuropsychopharmacology 33, 2187-2199. 
Light, G.A., Braff, D.L., 2005a. Mismatch Negativity Deficits Are Associated With Poor Functioning in 
Schizophrenia Patients. Archives of General Psychiatry 62(2), 127-136. 
Light, G.A., Braff, D.L., 2005b. Stability of Mismatch Negativity Deficits and Their Relationship to 
Functional Impairments in Chronic Schizophrenia. American Journal of Psychiatry 162(9), 1741-1743. 
Magno, E., Yeap, S., Thakore, J.H., Garavan, H., De Sanctis, P., Foxe, J.J., 2008. Are auditory-evoked 
frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-
density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic 
schizophrenia. Biol Psychiatry 64(5), 385-391. 
Markulev, C., McGorry, P.D., Nelson, B., Yuen, H.P., Schaefer, M., Yung, A.R., Thompson, A., Berger, 
G., Mossaheb, N., Schlogelhofer, M., Smesny, S., de Haan, L., Riecher-Rossler, A., Nordentoft, M., 
Chen, E.Y., Verma, S., Hickie, I., Amminger, G.P., 2015. NEURAPRO-E study protocol: a multicentre 
randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for 
patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv Psychiatry. 
McGorry, P., Keshavan, M., Goldstone, S., Amminger, G.P., Allot, K., Berk, M., Lavoie, S., Pantelis, C., 
Yung, A., Wood, S., Hickie, I., 2013. Biomarkers and clinical staging in psychiatry. World Psychiatry. 
 19 
McGorry, P.D., Nelson, B., Markulev, C., Yuen, H.P., Schafer, M.R., Mossaheb, N., Schlogelhofer, M., 
Smesny, S., Hickie, I.B., Berger, G.E., Chen, E.Y., de Haan, L., Nieman, D.H., Nordentoft, M., Riecher-
Rossler, A., Verma, S., Thompson, A., Yung, A.R., Amminger, G.P., 2017. Effect of omega-3 
Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The 
NEURAPRO Randomized Clinical Trial. JAMA Psychiatry 74(1), 19-27. 
Michie, P.T., Malmierca, M.S., Harms, L., Todd, J., 2016. The neurobiology of MMN and implications 
for schizophrenia. Biol Psychol 116, 90-97. 
Miller, T.J., McGlashan, T.H., Rosen, J.L., Somjee, L., Markovich, P.J., Stein, K., Woods, S.W., 2002. 
Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for 
Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J 
Psychiatry 159(5), 863-865. 
Mondragon-Maya, A., Solis-Vivanco, R., Leon-Ortiz, P., Rodriguez-Agudelo, Y., Yanez-Tellez, G., 
Bernal-Hernandez, J., Cadenhead, K.S., de la Fuente-Sandoval, C., 2013. Reduced P3a amplitudes in 
antipsychotic naive first-episode psychosis patients and individuals at clinical high-risk for psychosis. 
J Psychiatr Res 47(6), 755-761. 
Murphy, J.R., Rawdon, C., Kelleher, I., Twomey, D., Markey, P.S., Cannon, M., Roche, R.A., 2013. 
Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for 
mismatch negativity as a possible biomarker for vulnerability to psychosis. BMC Psychiatry 13, 45. 
Näätänen, R., Gaillard, A.W.K., Mantysalo, S., 1978. Early selective-attention effect on evoked 
potential reinterpreted. Acta Psychologica 42(4), 16. 
Näätänen, R., Paavilainen, P., Rinne, T., Alho, K., 2007. The mismatch negativity (MMN) in basic 
research of central auditory processing: a review. Clin Neurophysiol 118(12), 2544-2590. 
Naatanen, R., Shiga, T., Asano, S., Yabe, H., 2015. Mismatch negativity (MMN) deficiency: a break-
through biomarker in predicting psychosis onset. Int J Psychophysiol 95(3), 338-344. 
Naatanen, R., Todd, J., Schall, U., 2016. Mismatch negativity (MMN) as biomarker predicting 
psychosis in clinically at-risk individuals. Biol Psychol 116, 36-40. 
Nagai, T., Tada, M., Kirihara, K., Yahata, N., Hashimoto, R., Araki, T., Kasai, K., 2013. Auditory 
mismatch negativity and P3a in response to duration and frequency changes in the early stages of 
psychosis. Schizophr Res 150(2-3), 547-554. 
Nelson, B., Hughes, A., Leicester, S., Stratford, J., Polari, A., Highes, F., Yung, A., Group, T.P.M.W., 
2014. A Stitch in time: Interventions for young people at ultra high risk for psychosis. , Melbourne. 
Nelson, B., Yuen, H.P., Wood, S.J., Lin, A., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, 
M., Foley, D.L., Brewer, W.J., Francey, S.M., Amminger, G.P., Thompson, A., McGorry, P.D., Yung, 
A.R., 2013. Long-term Follow-up of a Group at Ultra High Risk ("Prodromal") for Psychosis: The PACE 
400 Study. JAMA Psychiatry 70(8), 793-802. 
Oades, R.D., Wild-Wall, N., Juran, S.A., Sachsse, J., Oknina, L.B., Ropcke, B., 2006. Auditory change 
detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in 
patients with a first episode in adolescence, and patients 14 years after an adolescent illness-onset. 
BMC Psychiatry 6, 7. 
 20 
Pantlin, L.N., Davalos, D., 2016. Neurophysiology for Detection of High Risk for Psychosis. Schizophr 
Res Treatment 2016, 2697971. 
Perez, V.B., Woods, S.W., Roach, B.J., Ford, J.M., McGlashan, T.H., Srihari, V.H., Mathalon, D.H., 
2014. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: 
forecasting psychosis risk with mismatch negativity. Biol Psychiatry 75(6), 459-469. 
Randeniya, R., Oestreich, L.K.L., Garrido, M.I., 2017. Sensory prediction errors in the continuum of 
psychosis. Schizophr Res. 
Rasser, P.E., Schall, U., Todd, J., Michie, P.T., Ward, P.B., Johnston, P., Helmbold, K., Case, V., 
Soyland, A., Tooney, P.A., Thompson, P.M., 2011. Gray matter deficits, mismatch negativity, and 
outcomes in schizophrenia. Schizophr Bull 37(1), 131-140. 
Salisbury, D.F., Kuroki, N., Kasai, K., Shenton, M.E., McCarley, R.W., 2007. Progressive and 
interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. 
Arch.Gen.Psychiatry 64(5), 521-529. 
Salisbury, D.F., Shenton, M.E., Griggs, C.B., Bonner-Jackson, A., McCarley, R.W., 2002. Mismatch 
Negativity in Chronic Schizophrenia and First-Episode Schizophrenia. Archives of General Psychiatry 
59(8), 686-694. 
Shaikh, M., Valmaggia, L., Broome, M.R., Dutt, A., Lappin, J., Day, F., Woolley, J., Tabraham, P., 
Walshe, M., Johns, L., Fusar-Poli, P., Howes, O., Murray, R.M., McGuire, P., Bramon, E., 2012. 
Reduced mismatch negativity predates the onset of psychosis. Schizophrenia Research 134(1), 42-
48. 
Shin, K.S., Kim, J.S., Kang, D.H., Koh, Y., Choi, J.S., O'Donnell, B.F., Chung, C.K., Kwon, J.S., 2009. Pre-
attentive auditory processing in ultra-high-risk for schizophrenia with magnetoencephalography. Biol 
Psychiatry 65(12), 1071-1078. 
Solís-Vivanco, R., Mondragón-Maya, A., León-Ortiz, P., Rodríguez-Agudelo, Y., Cadenhead, K.S., de la 
Fuente-Sandoval, C., 2014. Mismatch Negativity reduction in the left cortical regions in first-episode 
psychosis and in individuals at ultra high-risk for psychosis. Schizophr Res 158(1-3), 58-63. 
Todd, J., Michie, P.T., Schall, U., Karayanidis, F., Yabe, H., Naatanen, R., 2007. Deviant Matters: 
Duration, Frequency, and Intensity Deviants Reveal Different Patterns of Mismatch Negativity 
Reduction in Early and Late Schizophrenia. Biol.Psychiatry. 
Umbricht, D., Krljes, S., 2005. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr.Res. 
76(1), 1-23. 
Umbricht, D.S., Bates, J.A., Lieberman, J.A., Kane, J.M., Javitt, D.C., 2006. Electrophysiological indices 
of automatic and controlled auditory information processing in first-episode, recent-onset and 
chronic schizophrenia. Biol Psychiatry 59(8), 762-772. 
Valkonen-Korhonen, M., Purhonen, M., Tarkka, I.M., Sipila, P., Partanen, J., Karhu, J., Lehtonen, J., 
2003. Altered auditory processing in acutely psychotic never-medicated first-episode patients. 
Cognitive Brain Research 17(3), 747-758. 
van der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D.H., Yung, A.R., McGorry, P., Cuijpers, 
P., 2013. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention 
trials of 12 month and longer-term follow-ups. Schizophr Res 149(1-3), 56-62. 
 21 
Yung, A., Phillips, L., Yuen, H., McGorry, P., 2004. Risk factors for psychosis in an ultra high-risk 
group: psychopathology and clinical features. Schizophrenia Research 67(2-3), 131-142. 
Yung, A.R., Yuen, H.P., McGorry, P.D., Phillips, L.J., Kelly, D., Dell'Olio, M., Francey, S.M., Cosgrave, 
E.M., Killackey, E., Stanford, C., Godfrey, K., Buckby, J., 2005. Mapping the onset of psychosis: the 
Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 39(11-12), 964-971. 
 
  
 22 
9. Figure captions 
Figure 1 A) The average evoked potentials measured at Fz for both controls and 
UHR following the presentation of the standard and frequency-deviant sounds, and 
the difference wave between standard-evoked ERP and deviant-evoked ERP. The 
grey area designate the time interval during which the peak MMN amplitude was 
measured. B) Mean standard-evoked ERP amplitude, deviant-evoked ERP 
amplitude, and difference between both ERPs in controls and UHR. Error bars refer 
to standard error of the mean. 
Figure 2 A) Difference wave between standard-evoked ERP and deviant-evoked 
ERP for the UHR-NT and the UHR-T groups. The grey area designate the time 
interval during which the peak MMN amplitude was measured. B) Mean MMN 
magnitudes (standard – deviant; microvolts) in UHR-NT and in UHR-T. Error bars 
refer to standard error of the mean.  
 
 
 
Table 1. Characteristics of UHR participants who did not transition to psychosis 
(UHR-NT) and of those who transitioned to psychosis (UHR-T) within 12 months of 
study entry.
UHR-NT UHR-T
Characteristics (n = 21) (n = 6)
Gender, nb females (%) 14 (66.7) 3 (50.0)
Age (years), mean ± SD 17.9 ± 2.9 16.7 ± 1.3
SOFAS score 55.8 ± 9.3 57.3 ± 11.6
At-risk for psychosis group, nb (%)
   - attenuated symptoms 16 (76.2) 6 (100)
   - trait risk factor 2 (9.5) 0 (0.0)
   - BLIPS 0 (0.0) 0 (0.0)
   - attenuated symptoms + trait 3 (14.3) 0 (0.0)
Delay between baseline and follow-up EEG (days) 190.0 (17.4) 192.3 (130.3)
a Student's t-test
b Chi Square
Table 1
Figure 1
Click here to download high resolution image
Table 2. Characteristics of UHR participants randomized to the ω-3 PUFA group and 
the placebo group.
Placebo ω-3 PUFA
Characteristics (n = 10) (n = 13) p-value
Gender, nb females (%) 8 (80.0) 8 (61.5) .405
b
Age (years), mean ± SD 17.2 ± 2.7 17.9 ± 3.0 .575
a
SOFAS score 57.7 ± 12.9 55.1 ± 7.3 .705
a
At-risk for psychosis group, nb (%) .372
b
   - attenuated symptoms 9 (90.0) 9 (69.2)
   - trait risk factor 0 (0.0) 2 (15.4)
   - BLIPS 0 (0.0) 0 (0.0)
   - attenuated symptoms + trait 1 (10.0) 2 (15.4)
Baseline fMMN, mean ± SD 3.26 ± 2.34 3.67 ± 1.95 N/A
    Baseline 95% CI 1.88, 4.65 2.81, 5.47
Post-treatment fMMN, mean ± SD 4.14 ± 2.25 3.43 ± 1.61 N/A
    Post-treatment 95% CI 2.71, 4.62 2.65, 4.22
a Student's t-test
b Chi Square
Table 2
Figure 2
Click here to download high resolution image
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